Teladoc Health, Inc. (TDOC) Teladoc Health, Inc. offers remote medical services to individuals both domestically in the United States and internationally. Their extensive range of solutions covers a wide array of health needs, from routine and acute conditions to complex and long-term illnesses such as diabetes, hypertension, chronic kidney disease, cancer, congestive heart failure, and various mental health issues. The company delivers numerous programs, including virtual primary and specialized medical care, management for chronic diseases, expert second opinion services, mental wellness support, and core platform and service offerings. They serve a diverse client base, including corporations, health insurance providers, hospitals and healthcare systems, financial service companies, and individual patients. The Teladoc, Livongo, and BetterHelp brands fall under their purview. Founded in 2002, the company, which operated as Teladoc, Inc. until its renaming in August 2018, is based in Purchase, New York.
Sector: Services-Offices & Clinics of Doctors of Medicine
Industry: Medical - Healthcare Information Services
Teladoc Health, Inc. NYSE:TDOC Healthcare · Medical - Healthcare Information Services
Close $8.77 AH $8.75 Now $8.86 PM VOL 8K $ Vol ≈ $67K RVOL 0.83x
Close $8.77 -6.80% AH $8.75 +1.26% since
Mkt Cap $1.6B
PM VOL 8K sh
$ Vol ≈$67K
RVOL 0.83×
Press Release
Teladoc Health Announces Employee Inducement Awards under NYSE Rule 303A.08
Teladoc Health granted inducement RSU awards covering 40,768 shares to three employees who joined via the Teledigm Health acquisition, effective November 1, 2026.
The awards vest over three years and were approved by the Compensation Committee under the 2023 Employment Inducement Incentive Award Plan per NYSE Rule 303A.08.
This is routine administrative boilerplate with no financial or strategic significance beyond confirming onboarding of acquired personnel.
• 5d ago AI analysis › Press Release ● Major ⚠ 3
Teladoc Health Reports Third Quarter 2026 Results
Teladoc reported Q3 2026 revenue of $605.1 million, down 3% year-over-year, with adjusted EBITDA of $79.4 million up 14% and above its guidance range.
Integrated Care grew 2% to $398.5 million with an 18.8% EBITDA margin, while BetterHelp fell 13% to $206.6 million as out-of-pocket users declined 12%.
Net loss narrowed 46% to $26.9 million ($0.15 per share), and free cash flow was $75.9 million.
Full-year 2026 guidance calls for revenue of $2,395-$2,441 million and adjusted EBITDA of $277-$303 million, but the balance sheet shows $997.6 million of convertible notes now current against $849.9 million of cash.
• 11d ago AI analysis › Press Release
Gabelli To Host 8th Annual Healthcare Symposium
Gabelli Funds will host its 8th Annual Healthcare Symposium with Columbia Business School on November 13, 2026, at the Paley Center in New York, with a live webcast available.
AstraZeneca's Head of US Oncology, Mohit Manrao, is listed as a panelist on a session covering oncology innovation, alongside panelists from Gilead, Legend Biotech, Lilly, McKesson, Cencora, Optum, Teladoc, and InnovAge.
The release is a conference agenda announcement with no new corporate disclosure from AstraZeneca itself; it is informational only.
• 14d ago AI analysis › Press Release
Teladoc Health to Announce Third Quarter 2026 Financial Results
Teladoc Health will release third quarter 2026 results on Wednesday, October 28, 2026, after market close.
The company will host a conference call at 5:00 p.m. ET the same day, with a live webcast available on its investor relations site.
A replay of the call will be available on demand for approximately 90 days.
• 25d ago AI analysis › Press Release
Teladoc Health Expands Solo Connected Care Platform with AI-Powered Capabilities to Help Hospitals Scale Smarter Care Delivery
Teladoc Health announced two new AI-powered capabilities within its Solo enterprise platform for hospitals and health systems.
SoloVitals uses camera-based remote photoplethysmography to capture heart and respiration rates contactlessly, while SoloScribe generates ambient AI clinical notes that flow into the EHR; SoloScribe is generally available now and SoloVitals is in private preview with full release expected in December 2026.
The Solo platform is installed in more than 15,000 care locations globally with integrations into Epic and Oracle Health, and the launch positions Teladoc to compete on integrated AI-enabled care delivery for health systems.
• 1mo ago AI analysis › Press Release
Teladoc Health Announces Chief Legal Officer Transition
Teladoc Health announced Chief Legal Officer Adam Vandervoort will resign effective November 1, 2026, after 11 years with the company.
Jonathan Dorfman, currently SVP of Securities and Corporate Law, will be promoted to Chief Legal Officer and Secretary effective November 2, 2026.
Dorfman joined Teladoc in 2020 through the Livongo acquisition and has led SEC reporting, governance, capital markets and M&A legal work, giving the company continuity in the transition.
• 1mo ago AI analysis › Press Release
Teladoc Health Announces Employee Inducement Awards under NYSE Rule 303A.08
Teladoc Health granted employment inducement equity awards to Michael Grasher in connection with his commencing employment as Chief Financial Officer, effective September 1, 2026.
The package consists of restricted stock units covering 239,616 shares plus performance stock units with a target of 239,616 shares that can earn up to 479,232 shares. The PSUs vest based on 2026 adjusted EBITDA and Teladoc's actual revenue CAGR over 2026-2028.
The awards were approved by the Compensation Committee and granted under the 2023 Employment Inducement Incentive Award Plan pursuant to NYSE Rule 303A.08.
• 2mo ago AI analysis › Press Release
Teladoc Health Appoints Michael Grasher as Chief Financial Officer
Teladoc Health appointed Michael Grasher as Chief Financial Officer, effective immediately, to support its strategy for disciplined and sustainable growth.
Grasher brings over three decades of experience in financial services and insurance, having previously served as CFO at IFG Companies, Fortegra, and AMERISAFE.
CEO Chuck Divita highlighted Grasher's track record in financial stewardship and operational discipline as critical to executing the company's strategic priorities.
• 2mo ago AI analysis › Press Release
Teladoc Health Appoints Financial Executive Mark Anquillare to Its Board of Directors
Teladoc Health appointed Mark V. Anquillare, the former president and chief operating officer of Verisk Analytics, to its board of directors.
Mr. Anquillare will serve on the Audit & Compensation committees, bringing over 30 years of financial and executive leadership experience to the company.
Chairman Kenneth H. Paulus cited Anquillare's perspective on data, technology, and AI as invaluable as Teladoc Health evolves its strategy.
• 3mo ago AI analysis › Press Release ● Major ⚠ 5
Teladoc Health Reports Second Quarter 2026 Results
Teladoc reported Q2 revenue of $606.9 million, down 4% year-over-year, with a net loss of $38.9 million or $0.21 per share.
Integrated Care segment revenue grew 1% to $394.3 million with a 16.5% adjusted EBITDA margin, while the BetterHelp segment struggled with a 12% revenue decline to $212.6 million and margins shrinking to 0.2%.
Management lowered its BetterHelp revenue outlook due to accelerated pressure on cash pay revenue but maintained its full-year consolidated revenue and adjusted EBITDA guidance ranges.
• 3mo ago AI analysis › Press Release
Teladoc Health Canada Achieves Accreditation Canada Primer Award, Advancing Quality Standards for Virtual and Hybrid Care in Canada
businesswire.com • 3mo ago Press Release ● Major ⚠ 1
Teladoc Health introduces a virtual care practice built around the person, shaping a new era of connected care
Teladoc Health introduced Teladoc One, a new whole-person virtual care model designed to replace fragmented care with a connected, adaptive experience supported by multidisciplinary teams and AI.
The company is shifting to a value-based arrangement, placing 100% of its fees at risk by linking payment directly to clinical outcome measures and total cost of care improvements.
Programs under the new model will launch with select clients in September 2026, with broader availability expected in January 2027.
• 3mo ago AI analysis › Press Release
Teladoc Health to Announce Second Quarter 2026 Financial Results
Teladoc Health scheduled the release of its second quarter 2026 financial results for Wednesday, July 29, 2026, after the market closes.
The company will host a conference call to review the results at 5:00 p.m. ET on the same day.
Access information for the live webcast and replay will be available on the company's investor relations website.
• 3mo ago AI analysis › Press Release
Teladoc Health Announces Employee Inducement Award under NYSE Rule 303A.08
Teladoc Health granted an inducement award of 50,000 restricted stock units to David Packles, effective July 1, 2026, upon his commencement as Head of Product of BetterHelp.
The RSUs vest based on continued service, with one-third vesting on the first anniversary and the remaining shares vesting quarterly over the following two years.
The award was approved by the Compensation Committee under the 2023 Employment Inducement Incentive Award Plan in accordance with NYSE Rule 303A.08.
• 4mo ago AI analysis › Press Release
Teladoc Health Expands Access to Care Through Walmart’s Better Care Services
Teladoc Health announced that its virtual care services are now available through Walmart’s Better Care Services platform.
The integration offers Walmart customers access to virtual urgent care, dermatology, and nutrition services for a cash-pay price of $89 per visit.
This partnership expands Teladoc’s reach to millions of uninsured or underinsured consumers who already rely on Walmart for everyday needs, building on a previous integration with BetterHelp.
• 5mo ago AI analysis › Press Release ⚠ 2
Teladoc Health Reports First Quarter 2026 Results
Teladoc reported Q1 2026 revenue of $613.8 million, a 2% decrease from the prior year, with a net loss of $63.8 million or $0.36 per share.
Adjusted EBITDA came in at $58.2 million, flat year-over-year and exceeding the midpoint of the company's guidance range.
Management reaffirmed its full-year 2026 outlook, expecting revenue between $2.48B and $2.58B and Adjusted EBITDA between $267M and $306M.
• 6mo ago AI analysis › 
